Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 7/20 | 0.55 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | MLLT1 | Q03111 | 4/20 | 0.33 |
| ▸ | F9 | P00740 | 1/20 | 0.33 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293499 | 0.85 | NR3C1 (0.64) | NR3C1NAMPTMLLT1F9MLLT3 | |
| SCHEMBL12417949 | 0.71 | NR3C1 (0.39) | NR3C1CYP17A1 | |
| SCHEMBL5029899 | 0.71 | RIPK1 (0.43) | SCN5A | |
| SCHEMBL23686714 | 0.69 | DNMT1 (0.39) | NR3C1DNMT1SCN5AMLLT1MLLT3 | |
| SCHEMBL21388565 | 0.69 | MLLT1 (0.41) | NR3C1DNMT1SCN5AMLLT1MLLT3 | |
| SCHEMBL23230446 | 0.68 | DNMT1 (0.41) | NR3C1DNMT1SCN5AMLLT1MLLT3 | |
| SCHEMBL12418847 | 0.66 | NR3C1 (0.62) | NR3C1MAPK14 | |
| SCHEMBL9681514 | 0.64 | SLC6A4 (0.37) | SCN5A | |
| SCHEMBL30288156 | 0.64 | ESR1 (0.52) | NR3C1 | |
| SCHEMBL19117766 | 0.64 | TSHR (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994190-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100190820-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190820-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NR0B1, NR3C1, NFRKB | NR3C1 2/4885DNMT1 2402/4885SCN5A 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.